866-997-4948(US-Canada Toll Free)

Resistant Hypertension - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Dec 2016

Category :

Pharmaceutical

No. of Pages : 34 Pages

Resistant Hypertension - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Resistant Hypertension Pipeline Review, H2 2016, provides an overview of the Resistant Hypertension (Cardiovascular) pipeline landscape.

Resistant hypertension is defined as high blood pressure that remains uncontrolled despite treatment with antihypertensive agents. Causes of resistant hypertension include abnormalities in the hormones that control blood pressure, accumulation of artery-clogging plaque in blood vessels, obesity and sleep problems. This is handled by lifestyle alterations and regular medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Resistant Hypertension Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Resistant Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Resistant Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Resistant Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1 and 1 respectively.

Resistant Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Resistant Hypertension (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Resistant Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Resistant Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Resistant Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Resistant Hypertension (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Resistant Hypertension (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Resistant Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Resistant Hypertension Overview 6
Pipeline Products for Resistant Hypertension - Overview 7
Resistant Hypertension - Therapeutics under Development by Companies 8
Resistant Hypertension - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Resistant Hypertension - Products under Development by Companies 11
Resistant Hypertension - Companies Involved in Therapeutics Development 12
Bayer AG 12
Novartis AG 13
Sarfez Pharmaceuticals Inc 14
PhaseBio Pharmaceuticals Inc 15
Zumbro Discovery Inc 16
Resistant Hypertension - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
BAY-1636183 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
LHW-090 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
PB-1120 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
SP-20203 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
ZD-100 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Resistant Hypertension - Dormant Projects 31
Resistant Hypertension - Discontinued Products 32
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 33
Disclaimer 34

List of Tables
Number of Products under Development for Resistant Hypertension, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 9
Comparative Analysis by Early Stage Development, H2 2016 10
Products under Development by Companies, H2 2016 11
Resistant Hypertension - Pipeline by Bayer AG, H2 2016 12
Resistant Hypertension - Pipeline by Novartis AG, H2 2016 13
Resistant Hypertension - Pipeline by Sarfez Pharmaceuticals Inc, H2 2016 14
Resistant Hypertension - Pipeline by PhaseBio Pharmaceuticals Inc, H2 2016 15
Resistant Hypertension - Pipeline by Zumbro Discovery Inc, H2 2016 16
Assessment by Monotherapy Products, H2 2016 17
Number of Products by Stage and Target, H2 2016 19
Number of Products by Stage and Mechanism of Action, H2 2016 21
Number of Products by Stage and Route of Administration, H2 2016 23
Number of Products by Stage and Molecule Type, H2 2016 25
Resistant Hypertension - Dormant Projects, H2 2016 31
Resistant Hypertension - Discontinued Products, H2 2016 32

List of Figures
Number of Products under Development for Resistant Hypertension, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 9
Comparative Analysis by Early Stage Products, H2 2016 10
Assessment by Monotherapy Products, H2 2016 17
Number of Products by Targets, H2 2016 18
Number of Products by Stage and Targets, H2 2016 18
Number of Products by Mechanism of Actions, H2 2016 20
Number of Products by Stage and Mechanism of Actions, H2 2016 20
Number of Products by Routes of Administration, H2 2016 22
Number of Products by Stage and Routes of Administration, H2 2016 22
Number of Products by Molecule Types, H2 2016 24
Number of Products by Stage and Molecule Types, H2 2016 24

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *